NCT00366002

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or tolterodine extended release (ER) therapy.

Conditions

• Overactive Bladder (OAB)

Interventions

Type	Name	Description
DRUG	Darifenacin	Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily

Timeline

• Start date: 2006-06-01
• Completion: 2007-09-01
• First posted: 2006-08-18
• Last updated: 2008-01-15

Locations

82 sites across 1 country: United States